Hologic, Inc.'s (HOLX) robust strength in the molecular diagnostics business places it well for growth in the upcoming quarters. The company's Breast Health franchise is now more diverse with the newest acquisition. Sound financial stability also bodes well. Meanwhile, the impact of macroeconomic conditions and adverse currency fluctuations remain a concern for Hologic's operations. In the past year, this Zacks Rank #3 (Hold) stock has rallied 8.2% compared with the 11.8% growth of the industry and a 26.3% ...

Women's health innovator, Hologic (HOLX) , reported third-quarter fiscal 2024 results on Jul 29 after market close. Revenues exceeded both the company's internal forecasts and the Zacks Consensus Estimate. The bottom line topped the consensus mark, although the extent of surprise lowered by nearly 37% than the previous quarter. Additionally, the ongoing supply headwinds in the company's Skeletal Health business factored into narrowed EPS guidance for the year. Following the earnings release, the stock rose ...

(1) See accompanying notes. | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------|-------|---------------------------------|------------------------| | | | Nine Months \nJune 29, 2024 | Ended \nJuly 1, 2023 | | OPERATING ACTIVITIES | | | | | Net income | $ | 610.9 $ | 365.4 | | Adjustments to reconcile net income to net cash provided by operating activities: | | | | | Depreciation | | 75.2 | 66.7 | | Amortizat ...

Hologic, Inc. (HOLX) reported adjusted earnings per share (EPS) of $1.06 in the third quarter of fiscal 2024, up 14% year over year. The bottom line surpassed the Zacks Consensus Estimate by 3.9%. The adjustments include charges and benefits related to the amortization of acquired intangible assets, restructuring and integration/consolidation costs, product line discontinuation and many others. The company's GAAP EPS was 82 cents in the quarter compared to the year-ago quarter's loss of 16 cents. Revenues i ...

The reported revenue compares to the Zacks Consensus Estimate of $1 billion, representing a surprise of +1.07%. The company delivered an EPS surprise of +3.92%, with the consensus EPS estimate being $1.02. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Revenue- GYN Surgical: $166.60 million versus $166.70 million estimated by four a ...

Hologic (HOLX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.93 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarters, the company has surpassed consensus EPS estimates four times. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earn ...

Hologic Announces Financial Results for Third Quarter of Fiscal 2024 "In our third quarter of fiscal 2024, Hologic returns to top-line reported growth and once again exceeded the high-end of our guidance for both the top and bottom-line," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Our strong fiscal quarter and year-to-date results continue to highlight the durable strength across our broad portfolio, with our Diagnostics (ex-COVID), Breast Health, and Surgical ...

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding. Given this perspective, it's time to examine the average forecasts of specific Hologic metrics that are routinely monitored and predicted by Wall Street analysts. Analysts' assessment points toward 'Revenue- GYN Surgical' reaching $166.70 million. The estimate points to a chan ...

In the latest market close, Hologic (HOLX) reached $78.38, with a +0.35% movement compared to the previous day. This change lagged the S&P 500's 1.08% gain on the day. Meanwhile, the Dow experienced a rise of 0.32%, and the technology-dominated Nasdaq saw an increase of 1.58%. For the full year, the Zacks Consensus Estimates project earnings of $4.08 per share and a revenue of $4.04 billion, demonstrating changes of +3.03% and +0.13%, respectively, from the preceding year. Based on our research, we believe ...

Also, in April 2024, Hologic secured an Innovative Technology contract from Vizient for its CoolSeal advanced energy portfolio and JustRight 5 mm stapler. The recognition by Vizient's team of experts underscores the potential of these technologies to enhance clinical care, patient safety and healthcare worker safety and improve the business operations of healthcare organizations. We expect this development to have a positive impact on Hologic's revenues in the fiscal third quarter. Hologic, Inc.'s (HOLX) GY ...